|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00572624 |
Purpose
Obesity is one of the most widespread health problems of today, with more than 61 million adult Americans considered obese. Abdominal obesity (AO), in particular, is associated with an increased chance of cardiac diseases, such as coronary artery disease, and related risk factors, such as high blood pressure and type 2 diabetes mellitus (T2DM). Despite the known association between AO and cardiac disease, the mechanisms responsible for this relationship are still not well understood. Recent obesity studies have indicated that increased delivery of fats to the heart may play a role in heart function impairments. This study will evaluate the impact of AO on the human heart's use of fats for energy and on heart function.
| Condition | Intervention |
|---|---|
|
Obesity Diabetes Mellitus, Type 2 |
Behavioral: Weight Loss Management Program |
| Study Type: | Observational |
| Study Design: | Case Control, Prospective |
| Official Title: | Altered Myocardial Fatty Acid Metabolism In Obesity |
1 tablespoon of blood with DNA
| Estimated Enrollment: | 136 |
| Study Start Date: | June 2003 |
| Estimated Study Completion Date: | December 2008 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Participants characterized as overweight
|
Behavioral: Weight Loss Management Program
Selected overweight participants will set a goal of 10% body weight loss over a 6-month period, followed by a 1- to 2-month weight loss stabilization period. After the stabilization period, participants will undergo repeat abdominal fat and insulin sensitivity studies and imaging tests.
|
|
2
Participants characterized as lean
|
Obesity is defined as having a high amount of excess body fat. Millions of people worldwide meet the criteria for obesity, making it one of the most pressing current health issues. The more body fat a person has, the more susceptible that person is to a number of life threatening diseases, including heart disease, type 2 diabetes, gallstones, certain cancers, and high blood pressure. A variety of factors can lead to obesity. These factors include family history and genetics, physical inactivity, metabolism, hormone imbalance, and environment. Past research suggests that an increased availability of fats in the body leads to increased fat uptake by the heart. The heart only needs a certain amount of fat for energy, which leaves the remaining fat in the heart tissue, possibly impairing proper heart function. However, more information on the mechanisms behind the effects of fats on heart metabolism is needed. This study will evaluate the impact of AO on the human heart's use of fats for energy and on heart function.
This study will enroll both overweight and lean participants who will attend 4 to 7 study visits. Visit 1 will consist of various screening tests, including a medical history, physical exam, pregnancy test if applicable, routine blood test, and an echocardiogram (ECHO) performed before and during exercise.
Visit 2 will consist of an abdominal fat and insulin sensitivity study. This will entail a magnetic resonance imaging (MRI) test to image the heart and stomach, a dual energy x-ray absorptiometry (DEXA) scan to measure total body fat and muscle content, and an insulin sensitivity test to measure how well the hormone insulin controls blood sugar. The latter test will require multiple blood draws over a 3-hour period.
Visits 3 and 4 will occur over a 2-week period. Both visits will consist of an overnight stay at the General Clinical Research Center (GCRC) followed by a day of imaging studies. During Visit 3, participants will first undergo a 4-hour whole body metabolism study, which will include injection of a nonradioactive tracer through previously placed IVs, blood draws, and breathing into a machine for approximately 15 minutes. Participants will then undergo a positron emission tomographic (PET) heart metabolism study, which will also involve tracer injections and blood draws. A resting ECHO test will also be done during the PET study. Participants will be asked for permission to store a sample of their blood for a period of up to 10 years to be used in future research studies on the heart. During Visit 4, participants will undergo repeat tests from the third visit, except the PET study will evaluate the heart's ability to use sugars instead of fats. This will complete the study visits for all lean participants and some overweight participants and will entail 4 weeks of participation.
Overweight participants may be asked to attend an additional three study visits during an 8-month weight management program at Washington University School of Medicine. Participants will aim to lose 10% of their body weight over a 6-month period and to maintain that weight loss for another 1- to 2-month stabilization period. At the end of the stabilization period, participants will undergo repeat abdominal fat and insulin sensitivity studies during Visit 5, repeat whole body metabolism and heart metabolism studies during Visit 6, and repeat whole body metabolism and glucose heart metabolism studies during Visit 7.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
The study population will include both overweight and lean subjects.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Debi Delano, MSN | 314-747-3876 | delanod@mir.wustl.edu |
| Contact: Kitty Krupp, RN | 314-747-0183 | kruppk@mir.wustl.edu |
| United States, Missouri | |
| Washington University Medical School | Recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Principal Investigator: Robert Gropler, MD | |
| Sub-Investigator: Linda Peterson, MD | |
| Sub-Investigator: Samuel Klein, MD | |
| Sub-Investigator: Pilar Herrero, MS | |
| Sub-Investigator: Victor Davila, MD | |
| Principal Investigator: | Robert Gropler, MD | Washington University Medical School |
More Information
| Responsible Party: | Washington University Medical School ( Robert Gropler, MD ) |
| Study ID Numbers: | 488, P01 HL013851-43, IRB# 03-0395, RDRC# 498F, GCRC# 915, 22 3272 52136 |
| Study First Received: | December 12, 2007 |
| Last Updated: | February 25, 2009 |
| ClinicalTrials.gov Identifier: | NCT00572624 History of Changes |
| Health Authority: | United States: Federal Government |
|
Abdominal Obesity Heart Metabolism Type II Diabetes Mellitus PET Fatty Acid |
|
Body Weight Signs and Symptoms Obesity Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus |
Nutrition Disorders Endocrine System Diseases Overweight Overnutrition Glucose Metabolism Disorders |